Amgen's dazodalibep Secures Phase III Success in Sjögren's Disease, Sending Stock Higher

SentiSense · Published · Updated

Amgen said its Phase 3 OASIZ 301 trial of dazodalibep met its primary endpoint in moderate-to-severe systemic Sjögren's disease, showing a statistical...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis